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Abstract Intracellular N-acetylglucosaminylmuramyl peptide-
binding proteins of murine macrophages and myelomonocytic
WEHI-3 cells were characterized. SDS-PAGE and Western
blotting revealed proteins with molecular masses of 18, 32 and 34
kDa retaining the ability to specifically bind glucosaminylmur-
amyl dipeptide. The inhibition analysis demonstrated that only
biologically active muramyl peptides but not inactive analogs or
fragments of glucosaminylmuramyl dipeptide could inhibit
glucosaminylmuramyl dipeptide-binding to these proteins. Pur-
ification of these proteins and sequencing of peptides obtained
after in-gel trypsin digestion enabled us to identify the above
mentioned proteins as histones H1 and H3. These findings
suggest that nuclear histones might be target molecules for
muramyl peptides.
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1. Introduction
N-Acetylglucosaminyl-L1-4-N-acetylmuramyl-alanyl-D-iso-
glutamine (GMDP), the prototype of muramyl peptides [1], is
a fragment of the bacterial cell wall demonstrating a variety of
biological activities. Its adjuvant and anti-tumor e¡ects, the
ability to induce non-speci¢c resistance to bacterial and viral
infections are well-documented [2]. GMDP activity is medi-
ated by a receptor mechanism. High a⁄nity GMDP-binding
sites were found on the macrophage plasma membrane as well
as inside macrophages, the number of internal binding sites
being two orders of magnitude higher than of membrane
counterparts [3]. These internal binding sites were capable of
transducing a biological signal as was demonstrated using lip-
osome-encapsulated GMDP [4], whereas the role of mem-
brane-binding sites remains unclear. Similar results were ob-
tained by others upon study of muramyldipeptide (MDP), a
close relative of GMDP [5^7].
Little data are available on molecular characteristics of
muramyl peptide-binding proteins. Tenu et al. demonstrated
the binding of a 125I-labelled aryl-azide derivative of MDP to
an intracellular 40^45 kDa protein in rabbit alveolar macro-
phages [7]. MDP was also reported by Karnovsky et al. to
bind in a competitive manner to serotonin receptors on mac-
rophages [8] and platelets [9]. The binding of soluble peptido-
glycan to the human monocyte surface antigen CD14 was
recently reported which could be inhibited by MDP assuming
its interaction with CD14 [10]. The properties of GMDP-bind-
ing proteins of murine peritoneal macrophages were reported
from this laboratory. A⁄nity labelling of permeabilized mur-
ine macrophages using the [125I]azidosalicyl derivative of
GMDP-lysine revealed that GMDP was binding speci¢cally
to 32^34 and 38 kDa proteins [11]. The former proteins were
detected also on Western blots with biotinylated GMDP-con-
taining polymeric probe, not only in murine macrophages and
myelomonocytic WEHI-3 cells, but in human, rat and mouse
T-helper cells as well [4]. In the present study, we report the
identi¢cation of 18, 32 and 34 kDa GMDP-binding proteins
(a preliminary report of this study was presented at the 13th
European Immunology Meeting, June 22^25, 1997, Amster-
dam [12]).
2. Materials and methods
2.1. Materials and reagents
Cell culture medium and supplements were obtained from Gibco
Life Technologies (UK). Chemicals and enzymes were purchased from
Sigma Chemicals (St. Louis, USA). Blotting membranes and mem-
brane ¢lters were obtained from Millipore (Moscow, Russia). Strep-
toavidin-horseraddish peroxidase conjugate was kindly provided by
Dr A. Zinchenko (Shemyakin-Ovchinnikov Institute of Bioorganic
Chemistry, Moscow, Russia).
2.2. Cells and cell cultures
WEHI-3 cells were grown in RPMI 1640 medium, supplemented
with 2 mM L-glutamine, 5U1035 M 2-mercaptoethanol and 10% fetal
calf serum (FCS).
Murine peritoneal macrophages were puri¢ed by adsorption to
plastic. Brie£y, mice were killed by cervical dislocation. Peritoneal
exudate cells were washed with medium 199, supplemented with 5%
(v/v) FCS and incubated in the same medium for 2 h in 10 cm plastic
Petri dishes. Non-adherent cells were washed out with Dulbecco’s
PBS. Macrophages were removed from plastic surface by a cell scra-
per.
2.3. Synthesis of GMDP and derivatives
GMDP and other glucosaminylmuramyl peptides were synthesized
as described by Rostovtseva et al. [13].
2.4. Synthesis of GMDP-lysine (20 mol%) and biotin (5 mol%)
attached to the linear polyacrylamide backbone ((GMDP-Lys)-
PAA-(Bi))
The synthesis of (GMDP-Lys)-PAA-(Bi) was accomplished by con-
jugation of N-acetylglucosaminyl-L1-4-N-acetylmuramyl-alanyl-D-iso-
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glutaminyl-lysine (GMDP-Lys) and biotin to activated acrylic acid
polymer as was described by Bovin et al. [14].
2.5. Electrophoresis and Western blotting
Electrophoresis was carried out according to Laemmli in 10 or 12%
polyacrylamide slab gels [15]. Proteins were blotted onto a nitrocellu-
lose membrane using a semi-dry blotter (Ancos, Denmark) according
to the instructions of the manufacturer.
Blotting onto an Immobilon membrane was carried out as in [16].
The membrane was soaked for 10 min in methanol and then in blot-
ting bu¡er. The blotting was performed in 25 mM sodium bicarbon-
ate, pH 8.5, containing 10% methanol, for 2 h at 0.8 mA/cm2. The
Immobilon membrane was stained with 0.1% Coomassie R-250 in
50% aqueous methanol for 3^5 min and destained with the same
solvent.
2.6. Detection of GMDP-binding proteins on Western blots
The membranes were incubated (4‡C, 18 h) in 1% BSA solution in
PBS, pH 7.4, in order to block remaining protein-binding sites and
then washed three times with PBS, containing 0.1% Tween-20, and
three times with PBS. The same procedure was repeated between each
of the remaining steps. The membranes were incubated with 1 Wg/ml
(GMDP-Lys)-PAA-(Bi) or the similar probe with D-glucose residues
substituted for GMDP-Lys ((Glc)-PAA-(Bi)) at 22‡C for 1 h and then
treated with streptoavidin-peroxidase conjugate (1 Wg/ml) for 1 h at
the same temperature. The solution of 10 mg 4-chloro-1-naphtol, 3 mg
3,3P-diaminobenzidine and 20 Wl 30% hydrogen peroxide in the
mixture of 10 ml PBS and 5 ml methanol was used for visualization
of the bound conjugate.
In case of inhibition analysis, equal amounts of macrophage lysate
protein were applied to lanes of a slab gel. After SDS-PAGE and
Western blotting, the blot was cut into strips and each strip was
incubated with (GMDP-Lys)-PAA-(Bi) in the presence or absence
(control) of inhibitor, namely MDP (5 mg/ml), GMDP (5 mg/ml),
N-acetylglucosaminyl-L1-4-N-acetylmuramyl-alanyl-L-isoglutamine
(LL-GMDP) (5 mg/ml), N-acetylglucosaminyl-L1-4-N-acetylmuramyl-
alanyl-D-isoglutaminyl-(NO-stearoyl)lysine (GMDP-(stearoyl)Lys) (5
mg/ml), disaccharide GlcNAc-MurNAc (2.5 mg/ml) or dipeptide
Ala-D-iGln (2.5 mg/ml).
2.7. Solubilization of GMDP-binding proteins
Cells were lysed with hypotonic bu¡er (2 mM Tris-HCl, pH 7.6,
1 mM CaCl2, 1 mM phenylmethylsulfonyl £uoride). The lysate was
spun at 102 000Ug for 1 h. The pellet was treated with 2 M KCl (KCl
extract) in the case of macrophages or 2 mM Tris-HCl, pH 7.6, with
0.01 M Na-EDTA in the case of WEHI-3 cells (EDTA extract) at
22‡C. Suspensions were centrifuged at 102 000Ug for 1 h and super-
natants were kept for further experiments.
2.8. Ion-exchange HPLC
A TSK DEAE-5PW column (LKB, Sweden) was equilibrated with
20 mM Tris-HCl, pH 7.6, containing 2 mM Na-EDTA. EDTA ex-
tract of WEHI-3 cells (2^5 mg of protein) was applied and the column
was washed with the above bu¡er until unbound proteins were eluted.
A linear NaCl gradient (0^0.5 M) was applied. Fractions were lyophi-
lized.
To assay GMDP-binding activity, 100 ml of each fraction was
analyzed. Proteins were precipitated by addition of trichloroacetic
acid (TCA) to make the ¢nal concentration 10%. After 30 min incu-
bation at 4‡C, the precipitate was collected by centrifugation
(10 000Ug, 5 min). Samples were prepared for SDS-PAGE and run
in 12% slab gels. GMDP-binding proteins were detected after blotting
using (GMDP-Lys)-PAA-(Bi) probe as described above.
2.9. Gel ¢ltration
HPLC puri¢cation of macrophage KCl extract was performed on a
G2000SW column (Toya Soda, Japan). The column was equilibrated
with 20 mM Tris-HCl, pH 7.6, containing 2 mM Na-EDTA and 0.5
M NaCl. Fractions (1 ml) were analyzed as described for ion-ex-
change HPLC.
2.10. Proteinase treatment
WEHI-3 cells or peritoneal macrophages were incubated in six well
plates (3^5U105 cells per well) at 37‡C in an atmosphere of 5% CO2,
overnight. The adherent cells were washed with PBS and treated with
1^2 U trypsin, papain or pronase in 1 ml PBS. In the case of papain,
Na-EDTA and 2-mercaptoethanol were also added (1 and 25 mM,
respectively). Proteolysis was monitored by light microscopy. When
cells dissociated from the plastic surface, the appropriate proteinase
inhibitors were added (1 mM phenylmethylsulfonyl £uoride, 10 mM
iodoacetamide or 10 mg/ml soybean inhibitor, respectively). Cells
were sedimented by centrifugation, dissolved in Laemmli sample
bu¡er and subjected to SDS-PAGE. GMDP-binding proteins were
visualized with (GMDP-Lys)-PAA-(Bi) as described above.
2.11. Protein assay
Proteins were precipitated with TCA (5% ¢nal concentration) for
30 min. The precipitate was sedimented by centrifugation (10 000Ug,
5 min) and washed with 2% aqueous TCA. A sodium hydroxide
solution (1 N, 0.4 ml), containing 0.05% SDS, was added and the
mixture was carefully heated to solubilize the precipitate. The Lowry
method was used to assess the protein content [17].
2.12. Protein sequence analysis
In order to prepare samples for N-terminal analysis, lyophilized
fractions, containing GMDP-binding proteins, were dissolved in 100
Wl deionized water. Methanol (100 Wl) and chloroform (200 Wl) were
added and centrifugation was carried out at 6000Ug for 5 min. To
collect proteins, which formed a ¢lm at the interphase, solvents were
removed with the syringe. The protein ¢lm was dried, dissolved in the
sample bu¡er and subjected to SDS-PAGE in a 12% gel. After elec-
trophoresis, proteins were blotted onto an Immobilon membrane. The
stained bands were excised from the Immobilon membrane and sub-
jected to N-terminal sequencing using an Applied Biosystems model
470A solid-phase sequencer (USA).
For peptide mapping after SDS-PAGE, the gels were stained with
Coomassie blue R-250, destained and dried. The corresponding pro-
tein bands were excised and digested in situ with trypsin according to
Hellman et al. [18]. The peptides were separated by reverse phase
(RP)-HPLC on a 5 mm C18 Vydac resin using a linear gradient
from 98% A (0.1% TFA in water) to 92% B (90% acetonitrile in
0.1% TFA/water) in 60 min and monitored at 214 nm. The HPLC
system, UV detection and column construction have been extensively
described by Swiderek et al. [19]. The peptides were microsequenced
on a HP G1005A sequencer (Hewlett Packard, Palo Alto, CA, USA).
The sequencing system was operated using standard reagents, solvents
and programs (Routine 3.0) as supplied by the manufacturer.
3. Results and discussion
When photoa⁄nity labelling was used to identify GMDP-
binding proteins, several molecules were labelled in permeabi-
lized macrophages, but only the binding to proteins with mo-
lecular masses of 31^34, 38 and 43 kDa was markedly inhib-
ited by cold GMDP [11]. The 40^45 kDa protein was
identi¢ed using the same technique as the target molecule
for MDP in rabbit alveolar macrophages by Tenu et al. [7].
The similarity between the rabbit 40^45 kDa protein and the
murine 43 kDa GMDP-binding protein was strengthened by
the fact that a non-labelled azidosalicyl derivative of the cor-
responding muramyl peptide was a much more e¡ective inhib-
itor of binding than non-modi¢ed muramyl peptide.
We found that the proteins with molecular masses of 18, 32
and 34 kDa (Fig. 1, lane 1) (further designated p18, p32 and
p34, respectively) were able to speci¢cally interact with
GMDP after SDS-PAGE and Western blotting [20]. The
new type of probes (GMDP-Lys)-PAA-(Bi) with multiple li-
gand (GMDP-Lys) and biotin residues attached to the linear
polyacrylamide backbone was used to demonstrate this (for
review see [21]). They enable to detect ligand-protein interac-
tion with an extremely high sensitivity. (GMDP-Lys)-PAA-
(Bi) contained 20 mol% GMDP-lysine and 5 mol% biotin
residues. No bands were observed upon staining with the sim-
ilar polyacrylamide-based probe (Glc)-PAA-(Bi) in which
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D-glucose residues were incorporated instead of GMDP-Lys
(data not shown). Therefore, GMDP-Lys rather than the
PAA-(Bi) matrix was responsible for binding.
Staining the blots with (GMDP-Lys)-PAA-(Bi) in the pres-
ence of a number of GMDP analogues, namely GMDP, LL-
GMDP, MDP, GMDP-(stearoyl)Lys, disaccharide GlcNAc-
L1^4-MurNAc or dipeptide Ala-D-iGln, showed that only
the biologically active muramyl peptides GMDP, MDP and
GMDP-(stearoyl)Lys e¡ectively inhibited the binding (Fig. 1,
lanes 2^4). To obtain e¡ective inhibition, the inhibitor had to
be present in a large excess to conjugated GMDP, evidently,
because of multipoint binding of the conjugate to blotted
proteins which increased greatly the strength of binding.
This e¡ect is well known, e.g. for IgM antibodies. The lip-
ophylic GMDP-(stearoyl)Lys was the most e¡ective inhibitor.
This could be due to additional non-speci¢c interactions of
the stearoyl residue with side chains of hydrophobic amino
acids of the receptor proteins. GMDP was a more e¡ective
inhibitor than MDP, suggesting that a N-acetylglucosamine
residue contributed to binding. An intact glycopeptide mole-
cule was required because disaccharide and dipeptide frag-
ments of GMDP were ine¡ective (Fig. 1, lanes 6, 7). The
absence of inhibitory activity of LL-GMDP (Fig. 1, lane 5)
indicated that the stereochemistry of an isoglutamine residue
was also important. These results were in agreement with the
speci¢city of GMDP-binding sites detected in permeabilized
murine macrophages [3] as well as with structural require-
ments for biological activity of glucosaminylmuramyl peptides
[2], suggesting potential functional implications of binding to
p18, p32 and p34.
We used the protease protection assay to con¢rm that p18,
p32 and p34 were located inside the cells rather than on the
cell surface. The cells (murine peritoneal macrophages or
WEHI-3 cells) were treated with three proteases with di¡erent
speci¢cities (trypsin, papain or pronase) and in all three cases,
the GMDP-binding proteins remained intact, evidently due to
their intracellular location (data not shown).
Upon centrifugation of the lysates of the cells (either peri-
toneal macrophages or WEHI-3) at 102 000Ug for 1 h, p18,
p32 and p34 sedimented with the pellet indicating that these
were not soluble cytoplasmic proteins. These proteins were
solubilized, though when the pellets were treated with 2 M
KCl in the case of murine peritoneal macrophages and by 2 M
KCl or 0.01 M EDTA in the case of WEHI-3 cells. As was
shown by SDS-PAGE, this procedure enabled us to separate
GMDP-binding proteins from the bulk of cellular proteins.
We used the anion-exchange HPLC to purify the GMDP-
binding proteins from the WEHI-3 EDTA extract. Elution
with a NaCl gradient was employed. SDS-PAGE with subse-
quent Western blotting revealed that at a neutral pH, GMDP-
binding proteins eluted at the end of the gradient, later than
the majority of EDTA-solubilized proteins (Fig. 2).
In the case of macrophages, DEAE-chromatography could
hardly be used because of the high salt content in KCl extract.
Dialysis or dia¢ltration resulted in loss of p32 and p34, evi-
dently due to sticking to the membrane. Therefore, macro-
phage subcellular fragments were ¢rst extracted with 0.01 M
EDTA to partly remove contaminating proteins and then with
2 M KCl. The high pressure gel chromatography was em-
ployed to purify the GMDP-binding proteins from the KCl
extract. The bulk of GMDP-binding activity eluted as a 130^
Fig. 1. Inhibition of (GMDP-Lys)-PAA-(Bi)-binding to macrophage
lysate proteins on Western blots by GMDP, other muramyl peptides
and GMDP fragments. Macrophage lysate was subjected to SDS-
PAGE and Western blotting, followed by incubation of blots with
(GMDP-Lys)-PAA-(Bi) in the presence of inhibitors, namely
GMDP (lane 2), GMDP-(stearoyl)lysine (lane 3), MDP (lane 4),
LL-GMDP (lane 5), GlcNAc-MurNAc (lane 6), Ala-D-iGln (lane 7).
Bound (GMDP-Lys)-PAA-(Bi) was visualized with streptoavidin-
peroxidase conjugate and peroxidase substrate. Lane 1, no inhibitor
(control). An equal amount of lysate protein was applied to each
lane.
Fig. 2. Puri¢cation of GMDP-binding proteins from WEHI-3 cells
by DEAE-HPLC. EDTA extract of WEHI-3 cells was subjected to
HPLC on a TSK DEAE-5PW column. Proteins were eluted with a
0^0.5 M NaCl gradient. 1, Protein pro¢le (OD226); 2, NaCl gra-
dient; 3, GMDP-binding activity.
Fig. 3. Puri¢cation of GMDP-binding proteins from murine macro-
phages by DEAE-HPLC. Gel ¢ltration of macrophage KCl extract
was carried out on a G2000SW HPLC column in 20 mM Tris-HCl
bu¡er, pH 7.6, containing 2 mM Na-EDTA and 0.5 M NaCl.
Hatched areas, GMDP-binding activity.
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140 kDa molecular mass protein (Fig. 3, fraction 7). Accord-
ing to SDS-PAGE carried out under non-reducing conditions,
this peak consisted of equivalent amounts of p32 and p34,
assuming a non-covalently linked oligomeric structure. The
p18 eluted as a broad peak within the 35^65 kDa molecular
mass interval (fractions 9, 10), indicating an oligomeric struc-
ture as well.
The GMDP-binding proteins from both macrophages and
WEHI-3 cells were further puri¢ed by SDS-PAGE and blot-
ted onto an Immobilon membrane for N-terminal sequencing.
In all cases, the N-terminal amino acid turned out to be
blocked. Therefore, to obtain sequence information after
SDS-PAGE, in-gel trypsin digestion was performed followed
by isolation of peptides by RP-HPLC. Sequencing of peptides
obtained from p32 and p34, isolated from either cell type,
matched sequence of histone H1 [22] (Fig. 4). The structure
of histones H1 is highly conserved between species. Their
calculated molecular mass is 21.5 kDa, but they were shown
to migrate on SDS-PAGE gels as 32^34 kDa proteins due to
high lysine content as was demonstrated, for instance, for the
human H1b protein [23].
The puri¢cation of p18 was achieved by SDS-PAGE of the
GMDP-binding fraction from DEAE-chromatography of
WEHI-3 cell lysate. The sequencing of two peptides obtained
after in-gel trypsin digestion matched the sequences of two
fragments corresponding to amino acids 42^50 and 74^78 of
the histone H3.1 [24].
Thus, GMDP-binding proteins, isolated by us, turned out
to be histones. Histones are known to be strongly basic pro-
teins which can bind acidic substances non-speci¢cally due to
ionic interactions. That this was not the case for GMDP was
proved by the inability of LL-GMDP, which had the same pI
value as GMDP, to inhibit GMDP interaction with histones.
Besides, the variation of the pH of bu¡er within the 4.5^7.5
range did not a¡ect the binding of (GMDP-Lys)-PAA-(Bi) to
receptor proteins con¢rming this conclusion (data not shown).
Histones are located predominantly in the cell nucleus,
though H1 protein was reported to be found on the cell sur-
face and cell cytoplasm as well [25]. Sorace and Johnson [26]
have shown that monoclonal anti-leukemic antibody capable
of binding to a wide variety of cell lines was speci¢c to histone
H1. Recently, Brix et al. [27] reported that extracellularly
occurring histone H1 mediated the binding of thyroglobulin
to the cell surface of mouse macrophages. Nevertheless, our
data [4] as well as data from other laboratory [5,6] favor the
intracellular location of functional muramyl peptide-binding
sites and, hence, possible involvement of nuclear histones in
GMDP activity.
GMDP is not unique among peptide immunomodulators in
its ability to bind to histones. Previously, prothymosin-a1, the
inducer of T-cell proliferation, was found by Papamarcaki et
al. [28] to interact with histone H1. Besides, a number of
polypeptide hormones were shown to have binding sites in
the cell nucleus, in particular, epidermal growth factor, nerve
growth factor, platelet-derived growth factor, etc. [29,30].
Their binding to chromatin was assumed to cause structural
alterations resulting in an increased DNA accessibility to tran-
scription factors and enzymes and leading to gene activation
[31^33]. Therefore, binding of GMDP to H1 is of particular
interest because it is thought to be primarily responsible for
the higher order organization of nucleosomes into the thick,
transcriptionally inert chromatin ¢ber [34]. It might be as-
sumed that GMDPs, upon interaction with histones, can loos-
en their binding to DNA, making gene regulatory sequences
more accessible to transcription enzymes and resulting in gene
expression. The gene-inducing activity of muramyl peptides,
in particular their e¡ect on cytokine genes expression, was
reported earlier [35,36]. The key question remains if muramyl
peptides can indeed enter the cell nucleus or not. Richerson et
al., using £uorescence microscopy, demonstrated the uptake
of FITC-labelled MDP-Lys by and accumulation inside rabbit
alveolar macrophages [37]. They observed both di¡use and
speckled cytoplasmic but not nuclear £uorescence. Neverthe-
less, these experiments do not exclude that muramyl peptides
can penetrate the nuclear membrane and bind to chromatin in
vivo because non-physiological conditions (4‡C) and a rela-
tively short incubation time (1 h) were used. Besides, bright
cytoplasmic £uorescence could hinder weak nuclear £uores-
cence. Our preliminary data obtained by using the laser scan-
ning confocal microscopy point out that this was the case. It
was shown that at 37‡C after 3 h (but not 1 h) incubation,
GMDP-Lys-FITC is found within the macrophage nucleus.
The data obtained show that histones H1 and H3 can spe-
ci¢cally interact with muramyl peptides. It is still to be proved
that this interaction takes place in vivo, but in any case, it is
evident that there are a number of target molecules for mur-
amyl peptides in mammalian cells, among which are serotonin
receptors [8] and a few other proteins [7,11]. Thus, it can be
postulated that the observed variety of biological e¡ects of
muramyl peptides results from their interaction with a number
of cellular proteins.
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